<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715024</url>
  </required_header>
  <id_info>
    <org_study_id>HAURO-0605-TW</org_study_id>
    <nct_id>NCT02715024</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms</brief_title>
  <official_title>An Open-label, Randomized, Parallel Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Taiwan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin
      alone or in combination with solifenacin for the treatment in men with lower urinary tract
      symptoms (LUTS) including overactive bladder (OAB) symptoms in Taiwan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in International Prostate Symptoms Score (IPSS-(S)) from baseline to the end of treatment</measure>
    <time_frame>Baseline and end of treatment (up to 12 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of urgency episode per 24 hours from baseline to the end of treatment</measure>
    <time_frame>Baseline and end of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of micturitions per 24 hours from baseline to the end of treatment</measure>
    <time_frame>Baseline and end of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life index (I-PSS-(L)) from baseline to the end of treatment</measure>
    <time_frame>Baseline and end of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum flow rate (Qmax) and voided volume determined by uroflowmetry from baseline to the end of treatment</measure>
    <time_frame>Baseline and end of treatment (up to 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by adverse events</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by postvoid residual volume (PVR)</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Measured by bladder scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by vital signs</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by laboratory parameters</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Overactive Bladder</condition>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Tamsulosin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin + solifenacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>Oral</description>
    <arm_group_label>Tamsulosin alone</arm_group_label>
    <arm_group_label>Tamsulosin + solifenacin</arm_group_label>
    <other_name>Harnalidge® D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Oral</description>
    <arm_group_label>Tamsulosin + solifenacin</arm_group_label>
    <other_name>Vesicare®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs and symptoms of frequency and urgency related to benign prostatic
             hyperplasia for at least 3 months

          -  I-PSS(S) score of ≥ 12

          -  Maximum flow rate (Qmax) of 4 to15 mL/sec

          -  Mean urinary frequency of ≥ 8 micturitions per 24 hours and ≥ 1 episode of urgency per
             24 hours as verified by the 3-day micturition diary

          -  Benign digital rectal examination (DRE) result

        Exclusion Criteria:

          -  Clinically significant outflow obstruction

          -  Significant post void residue volume (PVR &gt;100ml)

          -  Prostate specific antigen (PSA) ≥10 ng/mL

          -  Previous or planned prostate surgery, including transurethral resection of the
             prostate (TURP)

          -  Transurethral microwave treatment (TUMT), transurethral needle ablation (TUNA), laser,
             or other invasive or minimally invasive procedures within 12 months

          -  Patient with a neurological cause for abnormal detrusor activity

          -  Patients with urinary tract infection, chronic inflammation, bladder stones, bladder
             neck, sclerosis, urethral stricture, prostatic cancer, severe vesical diverticulum

          -  Uncontrolled narrow angle glaucoma, urinary or gastric retention or any other medical
             condition which in the opinion of the investigator makes the use of anticholinergics
             contra-indicated

          -  Patients with any other complication which may cause voiding dysfunction

          -  Patients with severe hepatic dysfunction, severe renal dysfunction, severe
             cardiovascular disorder, orthostatic hypotension, or senile dementia

          -  Patients receiving any medication therapy for LUTS/BPH 2 weeks prior to the study

          -  Use of drugs to treat incontinence currently

          -  Hypersensitivity to tamsulosin and/or solifenacin or to any component of the
             formulation

          -  Any clinically significant condition, which in the opinion of the investigator makes
             the patients unsuitable for the trial

          -  Patients had taken any investigational drug in the previous 3 months prior to this
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Therapeutic Area Lead of Medical Affairs (Asia-Oceania)</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Taiwan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tamsulosin</keyword>
  <keyword>Solifenacin</keyword>
  <keyword>Lower urinary tract symptoms</keyword>
  <keyword>Overactive bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

